kidney disease glp 1 Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis Real-World Evidence for GLP-1 Receptor

This retrospective, observational study assessed persistence and adherence in patients with type 2 diabetes (T2D) initiating once-weekly or daily injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in US clinical practice

Small increases in training load (~30 mins above your usual baseline) show minimal impact on recovery metrics

Designed for Busy LifestylesWith just one glp-1 patch per day, you can integrate seamlessly into work, travel, or study

Get personalized GLP-1 weight loss program with meds like semaglutide & tirzepatide to lose fat, improve metabolism, and achieve lasting results

Strategies to ensure GLP1 access equity in diabetes and obesity care, prioritizing highrisk patients and promoting fair, datadriven treatment access.

16th Nov, 2025